The authors summarize findings in a single institution retrospective review of patients undergoing pre-discharge VTE screening after pneumonectomy for NSCLC and compare outcomes to an historic series of patients who did not have screening. Rates of VTE in the screened group were 8.9% at discharge, an additional 3.4% within 30 days postop, and 5.4% &
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung - Cancer
June 11, 2016
June 11, 2016
The author describes the growing role of SBRT in lung cancer therapy and the growing role of radiation oncologists in decision-making regarding lung cancer. The cautionary note is that surgeons need to remain actively involved in staging, patient assessment, and treatment recommendations.
Commentary:
June 7, 2016
This video demonstrates the surgical treatment of a 57-year-old patient with a neuroendocrine tumor in the apical segment of the right upper lobe.
June 4, 2016
The authors used data from the NCDB to assess long-term outcomes after SBRT (1,781) or lobectomy (13,562) for clinical stage I NSCLC in patients without important co-morbidities. Overall survival was significantly better after lobectomy for T1N0 (HR 0.38) and for T2N0 patients (HR 0.38). Propensity score matched patients (1781 pairs) also had signi
May 30, 2016
This video demonstrates the safe control of pulmonary artery bleeding, conversion to VATS lobectomy, and completion of the operation.
May 26, 2016
Michael Snee of St. James’s Institute of Oncology, Leeds, United Kingdom, gives an informative talk on stereotactic ablative radiotherapy (SABR).
May 16, 2016
A uniportal VATS posterior approach with a 4 cm single incision was used to treat a 57-year-old patient with metachronous single metastases in the left lower lobe.
May 5, 2016
The goal of this multicenter survey was to determine the psychological and social impact of incidental pulmonary nodule detection.
May 5, 2016
The FDA is assuming regulatory control over e-cigarettes. Sales of e-cigarettes will be banned to those <18 years old. In addition, warning labels will be required on all packages and all products are now subject to government approval.
May 5, 2016
This is an outstanding and provocative editorial comment concerning treatment costs of lung cancer based on an article published in the last issue of the European Respiratory Journal. It reveals discrepancies in access to new therapies based on therapeutic targets due to molecular testing and treatment costs.